Anteris Technologies Global Corp. (AVR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 5 | 6 | 3 | 3 | 3 | 2 | 2 | - |
| Operating profit | $m | -94 | -106 | ||||||
| Net profit | $m | -12 | -17 | -31 | -46 | -76 | -94 | -104 | -45 |
| EPS reported | $ | -2.55 | -2.76 | ||||||
| Operating cashflow per share | $ | -2.11 | -0.89 | ||||||
| Capex per share | $ | 0.05 | 0.02 | ||||||
| FCF per share | $ | -2.16 | -0.90 | ||||||
| Free cash flow | $m | -80 | -88 | ||||||
| Net debt | $m | -12 | -257 | ||||||
| Book value equity | $m | -0 | - | ||||||
| Book value per share | $ | -0.00 | 2.59 | ||||||
| Number of shares | m | 36.91 | 97.34 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1,980.52 | 3.50 | ||||||
| P/S LTM | x | 96.28 | 82.15 | ||||||
| P/FCF LTM | x | -2.31 | -2.09 | ||||||
| EV/EBITDA LTM | x | -1.88 | -1.73 | ||||||
| EV/Sales LTM | x | 90.90 | 278.73 | ||||||
| Earnings Yield LTM | % | -51.11% | -11.77% | ||||||
| FCF Yield | % | -43.30% | -47.81% | ||||||
| Quality | |||||||||
| ROE | % | +101230.1% | -77.66% | ||||||
| ROIC | % | -42.56% | -41.63% | ||||||
| Operating margin | % | -49.08% | -47.38% | ||||||
| Gross margin | % | -16.57% | +36.98% | ||||||
| FCF/Sales | % | -4169.2% | -3927.8% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -29.23% | -17.06% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -34.95 | -26.51 | ||||||
| Net Debt/EBITDA | x | 0.11 | 2.52 | ||||||
| EBIT/Net interest | x | -1,286.22 | -2,042.96 | ||||||
| Net debt/market cap | % | +0.33% | +0.12% | ||||||
| Net debt/Equity | x | 128.73 | - | ||||||
| Gross debt/equity | x | -24.54 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Anteris Technologies Global Corp. (AVR)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free